Amgen Q3 2026 Results: Net Income $3.86 Billion on Revenue of $10.37 Billion
- US stocks
- Earnings
- Health Care

Amgen (Nasdaq: AMGN) said on 3 Nov 2026 that GAAP revenue for the third quarter of 2026 was $10.4 billion and GAAP net income was $3.86 billion. Diluted EPS was $7.08 on a GAAP basis, and adjusted EPS, a company-defined measure, was $6.45.
Key highlights
- Revenue (GAAP): $10.4 billion, up 8.5% YoY and 3.1% QoQ
- Net income (GAAP): $3.86 billion, up 20.1% YoY and 62.7% QoQ
- Diluted EPS (GAAP): $7.08, up 19.4% YoY and 62.0% QoQ
- Adjusted EPS (company-defined): $6.45, up 14% YoY
- Free cash flow (company-defined): $3.7 billion, against $4.2 billion a year earlier
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 10,365.0 | 9,557.0 | +8.5% | 10,054.0 | +3.1% |
| 3,710.0 | 2,526.0 | +46.9% | 3,514.0 | +5.6% | |
| Operating margin | 35.79% | 26.43% | +9.36 pp | 34.95% | +0.84 pp |
| 3,864.0 | 3,216.0 | +20.1% | 2,375.0 | +62.7% | |
| Net income margin | 37.28% | 33.65% | +3.63 pp | 23.62% | +13.66 pp |
| Diluted EPS ($) | 7.08 | 5.93 | +19.4% | 4.37 | +62.0% |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows revenue of $10.4 billion, up 8.5% from $9.56 billion a year earlier and up 3.1% from $10.1 billion in the second quarter of 2026. GAAP operating income rose 46.9% from a year earlier to $3.71 billion, and net income rose 20.1% to $3.86 billion.
On the table's basis, operating margin was 35.8% of revenue, against 26.4% a year earlier. The release gives its own GAAP operating margin of 37.5%, measured on product sales, which is a different base.
Seventeen products grew at double-digit rates
Product sales were $9.88 billion in the quarter, up 8%. The company said the growth was driven by volume. It said seventeen products grew at least double digits and seventeen are annualizing at more than $1 billion.
Repatha sales rose 37% to $1.08 billion, and UPLIZNA sales rose 191% to $451.0 million; the release attributes the UPLIZNA increase mainly to volume. Prolia sales fell 45% to $632.0 million, and the company said multiple biosimilars have launched globally.
Adjusted figures exclude acquisition-related items
Adjusted (non-GAAP) figures are the company's own measure, computed by excluding items related to acquisitions, restructuring and certain other items. In the quarter, acquisition-related expenses of $881 million in cost of sales were excluded, along with $59 million of intangible asset impairment charges.
Non-GAAP operating income was $4,676 million, a 47.3% margin on product sales, and non-GAAP net income was $3,520 million. GAAP other income included $1,465 million of net gains from equity investments, which the company excludes. Operating cash flow was $4.24 billion and capital expenditures were $587.0 million; the company defines free cash flow as operating cash flow less capital expenditures.
The company expects 2026 revenue of $38.9 billion to $39.7 billion
For full-year 2026, the company expects GAAP EPS of $18.34 to $19.28 and non-GAAP EPS of $22.90 to $23.70. It also expects capital expenditures of about $2.6 billion and share repurchases of not more than $3.0 billion.
Inference
Per share, the release shows 546 million weighted-average diluted shares in the quarter against 542 million a year earlier. The company paid $1.40 billion in dividends and made no share repurchases under its program in the quarter. It declared a dividend of $2.52 per share on 30 Jul 2026, paid on 11 Sep 2026 to holders of record as of 21 Aug 2026, which the company said was a 6% increase from the same period in 2025.
The release does not give segment operating income or headcount, or a date for the FDA decision on TAVNEOS. The next dated step it gives is an FDA action on the biologics license application for ABP 206, which the company expects by the end of 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

